| Drug-induced methaemoglobinaemia: treatment issues MD Coleman, NA Coleman Drug safety 14, 394-405, 1996 | 471 | 1996 |
| Progress in the development of in vitro human-based alternatives to animal models MD Coleman Environmental Toxicology and Pharmacology 21 (2), 120-122, 2006 | 262 | 2006 |
| Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance MD Coleman British Journal of Dermatology 129 (5), 507-513, 1993 | 261 | 1993 |
| Human drug metabolism MD Coleman John Wiley & Sons, 2020 | 219 | 2020 |
| The use of cimetidine to reduce dapsone‐dependent methaemoglobinaemia in dermatitis herpetiformis patients. MD Coleman, LE Rhodes, AK Scott, JL Verbov, PS Friedmann, ... British journal of clinical pharmacology 34 (3), 244-249, 1992 | 135 | 1992 |
| Monitoring antioxidant effects using methaemoglobin formation in diabetic erythrocytes MD Coleman, HL Tolley, AK Desai The British Journal of Diabetes & Vascular Disease 1 (1), 88-92, 2001 | 127 | 2001 |
| Dapsone toxicity: some current perspectives MD Coleman General Pharmacology: The Vascular System 26 (7), 1461-1467, 1995 | 115 | 1995 |
| The use of cimetidine as a selective inhibitor of dapsone N‐hydroxylation in man. MD Coleman, AK Scott, AM Breckenridge, BK Park British journal of clinical pharmacology 30 (5), 761-767, 1990 | 107 | 1990 |
| Impact on environment, ecosystem, diversity and health from culturing and using GMOs as feed and food AM Tsatsakis, MA Nawaz, VA Tutelyan, KS Golokhvast, OI Kalantzi, ... Food and Chemical Toxicology 107, 108-121, 2017 | 106 | 2017 |
| The therapeutic use of lipoic acid in diabetes: a current perspective MD Coleman, RC Eason, CJ Bailey Environmental Toxicology and Pharmacology 10 (4), 167-172, 2001 | 101 | 2001 |
| Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention MD Coleman Toxicology 162 (1), 53-60, 2001 | 94 | 2001 |
| Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes. MD Coleman, AM Breckenridge, BK Park British journal of clinical pharmacology 28 (4), 389-395, 1989 | 89 | 1989 |
| In vitro Models for Seizure-Liability Testing Using Induced Pluripotent Stem Cells AI Grainger, MC King, DA Nagel, HR Parri, MD Coleman, EJ Hill Frontiers in neuroscience 12, 590, 2018 | 81 | 2018 |
| Toxicity of plant extracts containing pyrrolizidine alkaloids using alternative invertebrate models OC Seremet, OT Olaru, CM Gutu, GM Nitulescu, M Ilie, S Negres, ... Molecular Medicine Reports 17 (6), 7757-7763, 2018 | 68 | 2018 |
| Differentiating human NT2/D1 neurospheres as a versatile in vitro 3D model system for developmental neurotoxicity testing EJ Hill, EK Woehrling, M Prince, MD Coleman Toxicology 249 (2-3), 243-250, 2008 | 63 | 2008 |
| An investigation of the role of metabolism in dapsone‐induced methaemoglobinaemia using a two compartment in vitro test system. MD Tingle, MD Coleman, BK Park British journal of clinical pharmacology 30 (6), 829-838, 1990 | 60 | 1990 |
| A Preliminary Investigation into the Impact of a Pesticide Combination on Human Neuronal and Glial Cell Lines In Vitro MD Coleman, JD O'Neil, EK Woehrling, OBA Ndunge, EJ Hill, A Menache, ... Public Library of Science 7 (8), e42768, 2012 | 56 | 2012 |
| Structure and activity in assessing antioxidant activity in vitro and in vivo: A critical appraisal illustrated with the flavonoids GRMM Haenen, MJTJ Arts, A Bast, MD Coleman Environmental Toxicology and Pharmacology 21 (2), 191-198, 2006 | 54 | 2006 |
| NT2 derived neuronal and astrocytic network signalling EJ Hill, C Jiménez-González, M Tarczyluk, DA Nagel, MD Coleman, ... PloS one 7 (5), e36098, 2012 | 51 | 2012 |
| A dissection of SARS‑CoV2 with clinical implications F Stancioiu, GZ Papadakis, S Kteniadakis, BN Izotov, MD Coleman, ... International journal of molecular medicine 46 (2), 489-508, 2020 | 48 | 2020 |
